Amgen Reports Positive Dazodalibep Data for Sjogren's Syndrome

Amgen reported positive topline results from its pivotal dazodalibep study for adults with moderate-to-severe systemic Sjogren's syndrome. The favorable data strengthens Amgen's pipeline and potential for a new treatment option for the autoimmune disease.